OpenAlex
PricingAboutJobs
Log inGet started
Work

LBA31 High- vs low-dose pre-operative ipilimumab and nivolumab in locoregionally advanced urothelial cancer (NABUCCO cohort 2)

HTML

Year: 2021
Type: conference-abstract
Source: Annals of Oncology
DOI: 10.1016/j.annonc.2021.08.2107
Authors: J. Van Dorp, B.B.M. Suelmann, N. Mehra, M. Van Montfoort, N. Van Dijk, K. Hendricksen, J. de Feijter, T. Boellaard, A. Daletzakis, C.U. Blank, R. Meijer, T. van der Heijden, B.W.G. van Rhijn, M.S. van der Heijden
Institutions: The Netherlands Cancer Institute, University Medical Center Utrecht, Radboud University Medical Center
Language: English

Topic: Bladder and Urothelial Cancer Treatments
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Keywords: urothelial carcinoma, ipilimumab, nivolumab, neoadjuvant immunotherapy, cisplatin-ineligible patients, dose comparison, pathological complete response, immune-related adverse events, radical cystectomy, immune checkpoint inhibitors, treatment toxicity, surgical resection timing, progression-free survival
SDG: Good health and well-being

Open Access status: bronze

Funders: Bristol-Myers Squibb, GlaxoSmithKline, Novartis, Roche
OpenAlex ID: W3202811014
Cites:
Cited by: 8
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Supporters
Legal
Privacy
Accessibility
Terms